ReShape

About ReShape

ReShape Lifesciences Inc. is a publicly held medical device company concentrating on solutions for obesity and metabolic diseases. Founded in 2002, the company provides an integrated portfolio of products and services for weight management. The firm is strategically focused on delivering therapies that address health issues associated with obesity, such as diabetes and hypertension. ReShape Lifesciences generates revenue through its suite of medical products and telehealth services, with a trailing 12-month revenue of $6.45 million as of June 2025.

The company's history includes key strategic moves, such as a merger with Obalon Therapeutics and the acquisition of BarioSurg, Inc. The leadership team features individuals with deep experience in the bariatric and minimally invasive surgery sectors.

ReShape Lifesciences' offerings target both patients and healthcare providers. A cornerstone product is the FDA-approved Lap-Band® Program, a minimally invasive adjustable gastric banding system that offers a long-term alternative to more invasive surgical procedures like gastric bypass. Another key technology is the ReShape Vest™ System, a laparoscopically implanted medical device that reduces stomach volume without permanently altering anatomy; this product is currently investigational outside of the United States. Complementing its device portfolio is reshapecare®, a virtual health coaching service that connects patients with board-certified health coaches via video and text to support lifestyle changes across nutrition, exercise, sleep, and stress. The company also operates the ReShape Marketplace™, an e-commerce platform offering wellness products.